GARDNER, Mass., Feb. 11, 2016 -- Precision Optics Corporation, Inc. (OTCQB:PEYE) (the "Company") announced that it intends to release its financial results for the fiscal 2016 second quarter ended December 31, 2015 after market trading ends on Tuesday, February 16, 2016.
Management has scheduled a conference call for 4:30 p.m. ET on Wednesday, February 17th to review the Company's financial results and future outlook. Participants may dial into the following number to access the call: 1-866-652-5200 or 1-412-317-6060. Please ask to be joined into the Precision Optics conference call. A replay of the call can be accessed at 1-877-344-7529 or 1-412-317-0088 and passcode: 10081171 until March 2, 2016.
About Precision Optics Corporation
Precision Optics Corporation has been a leading developer and manufacturer of advanced optical instruments since 1982. Using proprietary optical technologies, the Company designs and produces next generation medical instruments, Microprecision™ micro-optics with characteristic dimensions less than 1 millimeter, and other advanced optical systems for a broad range of customers including some of the largest world-wide medical device companies. The Company's innovative medical instrumentation line includes state-of-the-art endoscopes and endocouplers as well as custom illumination and imaging products for use in minimally invasive surgical procedures. The Company believes that current advances in its proprietary micro-optics and 3D imaging technologies present significant opportunities for expanding applications to numerous potential medical products and procedures. The Company's website is www.poci.com. Investors can find Real-Time Quotes and market information for the Company on www.otcmarkets.com/stock/PEYE/quote.
Company Contact: PRECISION OPTICS CORPORATION 22 EAST BROADWAY GARDNER, MASSACHUSETTS 01440-3338 Telephone: 978-630-1800 Investor Contact: Kirin M. Smith, Chief Operating Officer PCG Advisory Group D: 646.863.6519 E: [email protected] www.pcgadvisory.com


AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Nvidia and Groq Strike Strategic AI Inference Licensing Deal
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Italy Fines Apple €98.6 Million Over App Store Dominance
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 



